Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $66,332.50 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $20.41, for a total transaction of $66,332.50. Following the transaction, the chief financial officer now owns 13,000 shares in the company, valued at $265,330. The trade was a 20.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.59, for a total value of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total value of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $21.25 on Thursday. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The company has a 50-day moving average of $21.89 and a 200 day moving average of $23.92. The firm has a market cap of $1.04 billion, a PE ratio of -11.18 and a beta of 1.04.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Enliven Therapeutics by 67.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company’s stock worth $984,000 after buying an additional 17,546 shares in the last quarter. Stempoint Capital LP bought a new position in shares of Enliven Therapeutics in the 4th quarter worth $2,176,000. Polar Capital Holdings Plc lifted its stake in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the last quarter. ProShare Advisors LLC boosted its position in Enliven Therapeutics by 29.5% during the fourth quarter. ProShare Advisors LLC now owns 12,229 shares of the company’s stock valued at $275,000 after purchasing an additional 2,788 shares in the last quarter. Finally, Patient Square Capital LP grew its stake in Enliven Therapeutics by 147.4% in the fourth quarter. Patient Square Capital LP now owns 224,038 shares of the company’s stock valued at $5,041,000 after purchasing an additional 133,466 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

ELVN has been the subject of several research reports. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. Robert W. Baird boosted their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Buy” and an average price target of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.